The FDA Just Told Six Popular Peptides to Get Lost

Meanwhile, Customs and Border Protection recently seized 5,000 smuggled peptide units from China. A Utah physician was indicted for selling misbranded imports to more than 200 patients. And on March 31, the FDA sent a warning letter to Gram Peptides for interstate sales violations. This isn't a few bad apples; the orchard has issues.

The GLP-1 Connection

The peptide crackdown doesn't exist in a vacuum. It's part of a much larger FDA campaign against compounded versions of GLP-1 drugs like semaglutide (the active ingredient in Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound).

Here's the timeline that matters: semaglutide came off the FDA's drug shortage list in February 2025. Once a drug is no longer in shortage, compounding pharmacies lose their legal cover to make copies. The FDA gave 503A pharmacies until April 22, 2025, and 503B facilities until May 22, 2025, to wind down semaglutide production. Tirzepatide's 503B deadline hit even earlier, on March 19.

By September 2025, the agency had fired off more than 50 warning letters to companies marketing compounded GLP-1s as if they were generics. It launched a new import alert (Green List Import Alert 66-80) to block questionable GLP-1 ingredients at the border. Inspections of foreign API manufacturers ramped up.

The message was clear: the party's over.

Who's Feeling the Pain

The fallout has been swift for some of the biggest names in direct-to-consumer health. Hims & Hers, the telehealth giant that had been selling compounded GLP-1 products, pulled its compounded GLP-1 pill from the market on February 6, 2026, the same day the FDA announced its intent to take further enforcement action. Previously, in fall 2025, the FDA had issued more than 40 warning letters and over 100 cease-and-desist notices targeting deceptive advertising.

Empower Pharmacy, one of the largest compounders in the country, faces scrutiny on multiple fronts: import alerts blocking non-approved API sources and re-inspection requirements every two years.

FDA Commissioner Marty Makary has signaled that illegal mass compounding of GLP-1 copies should effectively end. Given the pace of enforcement, that outcome looks realistic.

The Political Wild Card

Not everyone is on board with the FDA's approach. HHS Secretary Robert F. Kennedy Jr. has publicly advocated for reversing the peptide bans, arguing the review process lacks sufficient compounding expertise and gives presenters too little time to make their case. His influence could delay or soften full restrictions, creating a tug-of-war between regulators focused on safety data and political appointees sympathetic to the compounding industry.

Five additional peptides are still under review, with a decision expected by February 2027. The committee's next moves will reveal whether this crackdown is a blip or a permanent shift.

What This Means for the Market

The compounding pharmacy industry is at a crossroads. On one side: a $50 billion peptide market with booming consumer demand, especially for weight loss and anti-aging. On the other: an FDA that's deploying warnings, seizures, import alerts, and even working with the DEA to shut down non-compliant players.

For legitimate compounders, the path forward means proving quality, staying within legal boundaries, and potentially pursuing formal FDA approval pathways. That's expensive and slow, but it's the only route that doesn't end with a warning letter.

For patients, the short-term picture is murkier. Access to certain peptide therapies will narrow, pushing people toward FDA-approved (and often more expensive) branded drugs. The FDA argues that's the point: approved drugs come with safety and efficacy data that compounded versions simply don't have.

For the broader biotech and pharma industry, the crackdown is a tailwind. Every compounded semaglutide prescription that disappears is a potential customer for Novo Nordisk or Eli Lilly. The regulatory hammer isn't just protecting patients; it's protecting market share.

Whether you see this as the FDA doing its job or the government picking winners, one thing is certain: the era of loosely regulated peptide compounding is winding down fast. Six peptides just got their answer. The rest of the industry is still waiting for theirs.

The Gene Therapy Company Betting Against Million-Dollar Price Tags

Gene therapies can cost millions per patient, and most never achieve commercial success. Ocugen's CEO thinks the industry is solving the wrong problem, and he's betting the company on manufacturing scale and affordable pricing over scientific novelty.